Summary (tl;dr)

A new highly mutated COVID-19 subvariant, BA.3.2, nicknamed "Cicada," is trending due to its recent re-emergence and potential to evade existing immunity, prompting public health officials to monitor its spread and associated symptoms in 2026.

Essential Background

COVID-19, caused by the SARS-CoV-2 virus, has continuously evolved since 2020, leading to the emergence of numerous variants and subvariants. These variants, such as the Omicron lineage, often carry mutations that can affect transmissibility, disease severity, and the effectiveness of vaccines and prior immunity. Public health organizations worldwide rely on genomic and wastewater surveillance to track these changes and inform public health responses.

The Full Story

The Google search trend for "cicada covid variant ba 3.2" and "covid symptoms 2026" is driven by the emergence and increasing awareness of a new, heavily mutated Omicron subvariant officially known as BA.3.2, which has been informally dubbed the "Cicada" variant. First detected in South Africa in November 2024, the variant gained its nickname due to its initial appearance, a period of dormancy, and subsequent re-emergence, mirroring the life cycle of cicadas. The World Health Organization (WHO) classified BA.3.2 as a Variant Under Monitoring (VUM) in December 2025 due to its significant number of mutations—over 70 spike protein mutations compared to the original Wuhan strain, and 70-75 compared to recent dominant strains.

As of early 2026, the Cicada variant has been detected in at least 23 countries and 25-29 U.S. states, with its prevalence increasing in parts of Europe, including Denmark, Germany, and the Netherlands. While early data suggests BA.3.2 may have an enhanced ability to evade antibodies from previous infections or vaccinations, potentially leading to more breakthrough infections, there is currently no evidence indicating it causes more severe disease than other recent Omicron strains. Public health bodies like the CDC are actively evaluating its transmissibility, immune evasion capabilities, and clinical impact. Wastewater surveillance has played a crucial role in the early detection of BA.3.2 in the United States, often identifying its presence weeks before clinical samples.

The search for "covid symptoms 2026" reflects public interest in understanding how current variants, including Cicada, manifest. Symptoms associated with the Cicada variant are generally similar to those of other Omicron subvariants, primarily affecting the upper respiratory system. These include cough, fatigue, fever, body aches, sore throat, runny nose, and headache, with loss of taste or smell being less common now. Other circulating variants in 2026, such as "Nimbus" (NB.1.8.1) and "Stratus" (XFG), have also been associated with specific upper respiratory issues like a severe sore throat, heavy congestion, and a dry cough.

Why It Matters

The trending keywords highlight ongoing public concern about the evolving nature of COVID-19 and its potential impact. The emergence of highly mutated variants like Cicada raises questions about the long-term effectiveness of current vaccines against infection, though they are still expected to provide strong protection against severe illness. The focus on "covid symptoms 2026" indicates a continued need for awareness regarding how the virus presents, allowing individuals to identify potential infections, seek appropriate care, and take measures to prevent further spread. The ability of BA.3.2 to evade existing immunity suggests that periodic waves of infection may continue, reinforcing the importance of genomic surveillance and adaptability in public health strategies.

Geographic Location

• South Africa (first detected the BA.3.2 variant)
• United States (detection in travelers, clinical samples, and widespread in wastewater surveillance across 25-29 states)
• Denmark, Europe (increased prevalence of BA.3.2)
• Germany, Europe (increased prevalence of BA.3.2)
• Netherlands, Europe (increased prevalence of BA.3.2; first US detection in traveler from Netherlands)
• Australia (BA.3.2 circulating)
• Mozambique (BA.3.2 began spreading)